BioCentury
ARTICLE | Company News

Galapagos, ThromboGenics deal

April 4, 2016 7:00 AM UTC

Galapagos granted ThromboGenics exclusive, worldwide rights to develop and commercialize Galapagos’ integrin antagonist library. Galapagos will receive EUR1 million ($1.1 million) up front and is elig...